Health authorities issue a defect notification for several batches of the oral liquid version of gabapentin following the discovery of “particles” in the product. The warning covers batches manufactured by Relonchem, a pharmaceutical company. The notification is described as urgent and relates specifically to the liquid formulation of the nerve pain medicine, not necessarily to other forms such as tablets or capsules. The sources do not specify the nature or cause of the particles, or whether any patients have reported adverse effects. No details are provided in the supplied reports on the number of affected batches, affected lot numbers, distribution areas, or the extent of the recall or withdrawal. The announcements indicate that the defect has been identified through quality checks and has prompted regulators to alert healthcare providers and patients to the potential issue with the medication’s appearance or composition. The reports focus on the need for awareness and traceability for the implicated product batches.